Donate
Join Us

Press Releases

July 14, 2020
Genetic Editing Milestone in Mouse Model of Rett Syndrome
Editing technique repairs mutant MeCP2 RNA and restores MeCP2 protein function A genomic error that causes Rett Syndrome, a serious lifelong ...
March 17, 2020
RSRT Partners with VivoSense to Develop Digital Biomarkers
NEWPORT COAST, CA — VivoSense announces a series of new collaborations with the Rett Syndrome Research Trust (RSRT) to develop digital ...
January 30, 2020
We’ve awarded $8.6 million in 2019 to preeminent researchers in our pursuit of a cure.
TRUMBULL, CT — The Rett Syndrome Research Trust (RSRT) committed $8.6 million in 2019 for breakthrough research focused on curing Rett, ...
January 22, 2019
RSRT Awards $10 Million to Preeminent Researchers in Pursuit of Curing Devastating Neurological Disorder
TRUMBULL, CT — Thanks to a $10 million investment in Rett Syndrome research in 2018—the largest annual award since the organization was ...
September 25, 2018
RSRT Names Timothy A. Riley Chief Scientific Officer and Chief Business Officer; Randall Carpenter Transitions to Chief Medical Officer
TRUMBULL, CT — The Rett Syndrome Research Trust (RSRT) is delighted to announce that Timothy A. Riley, Ph.D. has joined the organization in the ...
June 14, 2018
Marc Tesler Joins Rett Syndrome Research Trust Board of Trustees
The Rett Syndrome Research Trust is pleased to announce that Marc Tesler has joined its Board of Trustees. Marc’s granddaughter, Magnolia, who ...
January 30, 2018
Rett Syndrome Research Trust Awards $6.2 Million in 2017 to Speed a Cure for Rett Syndrome
TRUMBULL, CT — The Rett Syndrome Research Trust (RSRT) announced today research awards of $6.2 million made in 2017. RSRT’s sole and urgent ...
January 25, 2018
James Wilson, MD, PhD, from the University of Pennsylvania, Joins the Rett Syndrome Research Trust Gene Therapy Consortium
TRUMBULL, CT — The Rett Syndrome Research Trust (RSRT) is pleased to announce that James Wilson, MD, PhD, director of the University of ...
October 5, 2017
RSRT Launches Rett Syndrome Clinical Trial Consortium with $1.8 Million Award
TRUMBULL, CT — The Rett Syndrome Research Trust (RSRT) announced today the launch of the Rett Syndrome Clinical Trial Consortium. The primary ...
June 7, 2017
AveXis to Advance Gene Therapy Program Initiated by the Rett Syndrome Research Trust
TRUMBULL, CT — The Rett Syndrome Research Trust (RSRT) is excited to announce that AveXis, Inc., has committed to advance a gene therapy ...
March 22, 2017
The Rett Syndrome Research Trust Announces Roadmap to Cure Devastating Neurological Disorder that Afflicts 350,000 Girls and Women
TRUMBULL, CT — The Rett Syndrome Research Trust (RSRT) announced today a historic plan to cure Rett Syndrome, a devastating neurological ...
July 25, 2016
Philanthropist Alba Tull Joins RSRT Board of Trustees – Tull Family Foundation Contributes $500,000 to Speed to a Cure
TRUMBULL, CT — The Rett Syndrome Research Trust (RSRT) is pleased to announce that Alba Tull has joined its Board of Trustees. Additionally, ...
July 7, 2016
ArmaGen and RSRT Collaborate to Develop Novel Therapeutic for the Treatment of Rett Syndrome
CALABASAS, CA/TRUMBULL, CT — ArmaGen, Inc., a privately held biotechnology company focused on developing revolutionary therapies to treat ...
March 8, 2016
Rett Syndrome Research Trust Awards $9 Million to Accelerate Translation of Lab Discoveries to the Clinic
Today the Rett Syndrome Research Trust (RSRT) announced research awards totaling nearly $9 million in 2015. This is the most research ever ...
February 24, 2016
RSRT Names Randall L. Carpenter as Chief Scientific Officer
The Rett Syndrome Research Trust (RSRT) is delighted to announce that Randall L. Carpenter is joining the organization in the role of Chief ...
November 25, 2015
MECP2 Duplication Syndrome is Reversible
The methyl CpG binding protein 2 gene (MECP2) produces a protein of the same name, the level of which is critical for normal brain function. ...
$40M
Take Action